ReviewJournal of thrombosis and thrombolysis2013
Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations.
Review in Journal of thrombosis and thrombolysis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Bioavailability of Orally Administered Drugs After Bariatric Surgery.Current obesity reports · 2024Review
- Long-Term Outcomes of Bariatric Surgery in Patients on Chronic Anticoagulation.Obesity surgery · 2023Article
- Direct oral Xa inhibitors for the treatment of venous thromboembolism after bariatric surgery.Blood advances · 2023Article
- Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series.Journal of thrombosis and thrombolysis · 2022Article
- Evaluation of characteristics and dosing regimens in patients with new or recurrent thrombosis on apixaban and rivaroxaban.Journal of thrombosis and thrombolysis · 2021Article
- Bariatric Surgery can Lower the Efficacy of DOACs.European journal of case reports in internal medicine · 2020Article
- How I treat cancer-associated thrombosis.ESMO open · 2020Review
- Therapeutic monitoring of rivaroxaban in dogs using thromboelastography and prothrombin time.Journal of veterinary internal medicine · 2019Article
- Diagnostic accuracy of thromboelastometry and its correlation with the HPLC-MS/MS quantification test.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2019Article
- Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance.The American journal of medicine · 2017Review
- [Monitoring of NOAC].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2017Article
- Postoperative Bleeding After Administration of a Single Dose of Rivaroxaban to a Patient Receiving Antiretroviral Therapy.Drug safety - case reports · 2015Article
- Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects?Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis · 2015Observational
- Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants.Blood research · 2014Review
- [Acquired bleeding disorders - diagnostic approach].Der Internist · 2014Review
- Use of hemodialysis for the treatment of intracerebral hemorrhage in patients on dabigatran with normal renal function.Clinical nephrology. Case studies · 2014Article
- New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness.Drug design, development and therapy · 2014Review
- Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation: a tentative approach based on routine laboratory tests.Journal of thrombosis and thrombolysis · 2014Article
- The role of prothrombin complex concentrates in reversal of target specific anticoagulants.Thrombosis journal · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To simplify and optimize oral anticoagulation, new target-specific oral anticoagulants (TSOAs) have been developed. The direct thrombin-inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban are the first such compounds to receive approval in certain countries for various indications. Due to the predictable pharmacokinetic and pharmacodynamic profiles of these drugs, routine monitoring of patients receiving TSOA therapy has not been considered necessary. However, it has now been realized that in routine clinical settings, there are several situations where it may be prudent to assess the level of TSOA anticoagulation. Several studies evaluating the influence of TSOAs on various coagulation assays have been performed to identify systems that can be used to monitor these drugs. With a particular focus on dabigatran and rivaroxaban, we will describe and discuss the potential of several methods for measuring the anticoagulant effect of TSOAs, as well as their methodological limitations and the restrictions in transferring their results into clinical context.
Indexed as
Identifiers
23512159What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.